AstraZeneca Delays Lung Cancer Trial Results to 2027
The pharmaceutical firm postpones its AVANZAR lung cancer trial data as analysts evaluate long-term earnings growth potential.
Updated on Oct. 27, 2026 in Asthma
Live Poll
Is now a good time to invest in pharmaceutical companies based on future drug trials?
AstraZeneca has pushed the release of its AVANZAR lung cancer trial results from late 2026 to the first quarter of 2027. The delay is attributed to a current lack of sufficient data regarding disease progression among the trial participants.
Why it matters
Successful results from these late-stage trials are expected to bolster investor confidence in the company's growth trajectory through 2030. These clinical milestones remain critical for unlocking projected peak sales exceeding $20 billion.
AstraZeneca trades at 15 times its 2027 earnings, with core earnings per share projected to grow 10% annually between 2027 and 2030. The company maintains a 40% growth premium compared to the broader sector.
The players
AstraZeneca
A multinational pharmaceutical and biotechnology company that focuses on research and development in areas including oncology, cardiovascular, and respiratory diseases.
JP Morgan
A global financial services firm that provides investment banking, financial services for consumers and small businesses, and commercial banking.
The details
The decision to reschedule followed a review during the European Society for Medical Oncology congress held in October 2026. JP Morgan analysts noted that success hinges on meeting specific statistical hurdles across patient groups.
Timeline
The AVANZAR trial results were originally scheduled for release in Q4 2026.
The European Society for Medical Oncology congress took place in October 2026.
The company now expects to release the AVANZAR trial results in Q1 2027.
Multiple late-stage trial results are anticipated throughout 2027.
Projected core earnings growth is expected to span the 2027 to 2030 period.
Health Landscape
The delay of the AVANZAR lung cancer trial highlights the volatility of pharmaceutical pipelines where growth is heavily contingent on precise data accumulation. This setback updates the timeline for clinical milestones that underpin long-term valuation models.
Patients and healthcare providers awaiting new treatment options must adjust expectations for when the AVANZAR study results will be available for clinical review. The delay necessitates a longer wait for potential advancements in lung cancer therapy and associated data.
The takeaway
Investment analysts continue to track trial progress as a primary indicator of future company performance and sector growth. Shareholders should monitor upcoming clinical readouts throughout 2027 to gauge if development goals remain on track.
Further reading
For more context on respiratory and pulmonary research, visit the Asthma section.
Live Poll
Is now a good time to invest in pharmaceutical companies based on future drug trials?
